RESUMO
<p><b>OBJECTIVE</b>To study the clinicopathologic features and biologic behavior of pediatric immature teratoma.</p><p><b>METHODS</b>The clinical data, pathologic features, immunohistochemical findings (for cyclin D1, P27 and Ki-67) and follow-up information of 39 cases of pediatric immature teratoma were analyzed.</p><p><b>RESULTS</b>Amongst the 39 cases studied, 12 arose in the sacrococcygeal region, 12 in testis, 5 in retroperitoneum, 4 in ovary, 4 in abdomen and 2 in mediastinum. Histologically, 16 cases were of grade 1, 8 cases of grade 2 and 15 cases of grade 3. Seven of the cases contained foci of yolk sac tumor. Immature neuroepithelial features used in histologic grading included the presence of primitive neural tubules, immature rosettes, undifferentiated neuroblastoma cells and primitive neuroectodermal structures. Immunohistochemical study showed that cyclin D1 was positive in 3 cases of grade 1 tumors, 4 cases of grade 2 tumors and 9 cases of grade 3 tumors. The positivity rates for p27 were 8, 3 and 6 cases respectively, while those for Ki-67 were 3, 4 and 13 cases respectively. Follow-up data were available in 30 cases. Three of them, including 2 cases with histologic grade 3 (with or without yolk sac tumor component), recurred after operation.</p><p><b>CONCLUSIONS</b>The expression of cyclin D1 and Ki-67 is a useful adjunct in histologic grading. On the other hand, p27 overexpression shows little correlation with tumor grade. The prognosis of immature teratoma in children is different from that in adults. Sacrococcygeal immature teratoma occurring in patients younger than 1 year old and with low histologic grade do not require postoperative chemotherapy if the tumor is completely excised. Similarly, for testicular immature teratoma occurring in patients below 1 year of age, regardless of tumor grading, need no adjunctive therapy. On the other hand, ovarian immature teratoma with high histologic grade requires postoperative chemotherapy, regardless of age of the patients. The presence of microscopic foci of yolk sac tumor is a useful predictor of recurrence in pediatric immature teratoma.</p>
Assuntos
Adolescente , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Ciclina D1 , Metabolismo , Tumor do Seio Endodérmico , Tratamento Farmacológico , Metabolismo , Patologia , Cirurgia Geral , Seguimentos , Antígeno Ki-67 , Metabolismo , Neoplasias do Mediastino , Tratamento Farmacológico , Metabolismo , Patologia , Cirurgia Geral , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Neoplasias Ovarianas , Tratamento Farmacológico , Metabolismo , Patologia , Cirurgia Geral , Antígeno Nuclear de Célula em Proliferação , Metabolismo , Neoplasias Retroperitoneais , Tratamento Farmacológico , Metabolismo , Patologia , Cirurgia Geral , Região Sacrococcígea , Taxa de Sobrevida , Teratoma , Tratamento Farmacológico , Metabolismo , Patologia , Cirurgia Geral , Neoplasias Testiculares , Tratamento Farmacológico , Metabolismo , Patologia , Cirurgia Geral , alfa-Fetoproteínas , MetabolismoRESUMO
<p><b>OBJECTIVE</b>To establish a protocol for the targeting gene therapy against cancer with rich epidermal growth factor receptor (EGFR).</p><p><b>METHODS</b>A recombinant pcDNA3.1-PE III mut was constructed and combined with a non-viral vector, a fusion protein histone H1, epidermal growth factor C-loop previously expressed by us, to be a protein-DNA complex in vitro. Using the complex to treat BT-325 and Hela cancer cells with EGFR and JK cells without EGFR. The killing rates of the cells was calculated after 48 h of incubation at 37 degrees C.</p><p><b>RESULTS</b>To BT-325 and Hela cells, the killing rates were 46.03% and 48.12% respectively. To JK cells, the complex had no killing function.</p><p><b>CONCLUSION</b>The protocol for targeting gene therapy against cancer with EGFR has been established successfully.</p>
Assuntos
Humanos , ADP Ribose Transferases , Genética , Farmacologia , Toxinas Bacterianas , Genética , Farmacologia , Sequência de Bases , Linhagem Celular Tumoral , Células , DNA , Genética , Exotoxinas , Genética , Farmacologia , Marcação de Genes , Terapia Genética , Vetores Genéticos , Histonas , Genética , Dados de Sequência Molecular , Receptores ErbB , Genética , Metabolismo , Proteínas Recombinantes de Fusão , Genética , Metabolismo , Farmacologia , Transfecção , Fatores de Virulência , Genética , FarmacologiaRESUMO
<p><b>OBJECTIVE</b>To create a gene transfer vehicle for targeting gene therapy of cancer with epidermal growth factor receptor overexpressing.</p><p><b>METHODS</b>Encoding sequences of the first domain of histone gene (H1) and EGF C-loop (EGFc) were obtained by PCR amplification. These two DNA fragments were ligated by EcoR I site, and cloned and sequenced. E. coli expression vector of the fusion gene was then constructed. The fusion protein H1EGFc was purified by specific band isolation from SDS-PAGE.</p><p><b>RESULTS</b>The molecular weight of purified protein was consistent with the designed request. Its purity reached 94.02%.</p><p><b>CONCLUSION</b>A fusion protein H1EGFc was expressed and purified.</p>
Assuntos
Humanos , Sequência de Aminoácidos , Sequência de Bases , Escherichia coli , Genética , Técnicas de Transferência de Genes , Terapia Genética , Vetores Genéticos , Histonas , Genética , Dados de Sequência Molecular , Engenharia de Proteínas , Receptores ErbB , Genética , Proteínas Recombinantes de Fusão , GenéticaRESUMO
The gene coding for beta-glycosidase (EC3.2.1.21) from Thermus nonproteolyticus HG102 has been cloned and expressed in E. coli. The gene open reading frame was 1311 bp and it codes for 436 amino acids. The deduced amino acid sequence of the enzyme showed identity with members of glycosyl hydrolase family I. The enzyme had high content of hydrophobic amino acid (Ala 12.8%, Leu 10.9%), Arg(9.6%), Glu(9.4%) and Pro(8.0%), but low content Cys(0.45%) and Met (0.9%). From the alignment of enzyme amino acid sequence with other glycosyl hydrolase family I members, Glu164 and Glu338 were predicated as the proton donor and nucleophile group. The DNASTAR program was used to predict the secondary structure. According to the Chou-Fasman model, the enzyme has 41.4% of alpha-helics, 16.2%, beta-strands, 14.4%, beta-turns. 14 of the 35 Pro were located at the second sites of beta-turns. Hydrophobic interaction, ion bond, alpha-helics and Pro had important contribution to Tn-gly thermostability.